Provided by Tiger Fintech (Singapore) Pte. Ltd.

bluebird bio

3.98
-0.0200-0.50%
Volume:88.38K
Turnover:352.24K
Market Cap:38.69M
PE:-0.12
High:4.04
Open:3.90
Low:3.86
Close:4.00
Loading ...

BRIEF-Bluebird Bio Announces 1-For-20 Reverse Stock Split

Reuters
·
05 Dec 2024

Bluebird Bio announces 1-for-20 reverse stock split

TIPRANKS
·
05 Dec 2024

bluebird bio Announces 1-for-20 Reverse Stock Split

THOMSON REUTERS
·
05 Dec 2024

bluebird bio Announces 1-for-20 Reverse Stock Split

Business Wire
·
05 Dec 2024

Bluebird Bio participates in CMMI Cell and Gene Therapy Access Model

TIPRANKS
·
04 Dec 2024

CMS enters agreement with Vertex, bluebird to improve access to gene therapies

Reuters
·
04 Dec 2024

BRIEF-bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Reuters
·
04 Dec 2024

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (Cmmi) Cell and Gene Therapy Access Model

THOMSON REUTERS
·
04 Dec 2024

bluebird bio Inc - States Can Opt in to Agreement Until February 28, 2025

THOMSON REUTERS
·
04 Dec 2024

CMS: 2 Drug Manufacturers With FDA-Approved Gene Therapies for Sickle Cell Disease to Participate in Cell & Gene Therapy Access Model With CMS

THOMSON REUTERS
·
04 Dec 2024

CMS: Cell & Gene Therapy Access Model Launches in Jan 2025, States May Choose to Begin Participation Anytime Between Jan 2025 & Jan 2026

THOMSON REUTERS
·
04 Dec 2024

FDA Probes Potential Life-Threatening Blood Cancer Risks Linked To Bluebird Bio's Skysona Gene Therapy

Benzinga
·
29 Nov 2024

Press Release: BLUE MOON METALS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER DISTRICTS FOR US$67.3M AND TO COMPLETE A MINIMUM C$30 MILLION EQUITY FINANCING

Dow Jones
·
28 Nov 2024

bluebird bio Shares Down 1.3% at $0.36 After FDA Probes Cancer Risks of Co's Gene Therapy

THOMSON REUTERS
·
28 Nov 2024

BUZZ-Bluebird falls as FDA weighs cancer risks of co's gene therapy

Reuters
·
28 Nov 2024

FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action

Reuters
·
28 Nov 2024